Strontium ranelate
Osseor, Protelos (strontium ranelate) is a small molecule pharmaceutical. Strontium ranelate was first approved as Protelos on 2004-09-20. It has been approved in Europe to treat postmenopausal osteoporosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | 1 | — | 4 | 2 | 8 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 1 | 2 | 3 |
| Metabolic bone diseases | D001851 | — | — | 1 | — | — | 1 | 1 | 3 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | — | — | 2 | 1 | 3 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | 1 | — | 1 |
| Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | — | — | 1 | — | 1 |
| Compliance | D003187 | — | — | — | — | — | 1 | — | 1 |
| Coronary disease | D003327 | — | — | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | 4 | 3 | — | — | 7 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 2 | — | 5 | 7 |
| Dentin sensitivity | D003807 | — | — | — | 1 | 2 | — | 5 | 7 |
| Neoplasms | D009369 | — | C80 | — | 3 | 2 | — | — | 5 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 2 | 2 | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | 1 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | 1 | — | 1 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 1 | — | 1 | 2 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 3 | 3 |
| Radiation exposure | D000069079 | — | — | — | — | — | — | 2 | 2 |
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 2 | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Choroidal neovascularization | D020256 | — | — | — | — | — | — | 1 | 1 |
| Pathologic neovascularization | D009389 | — | — | — | — | — | — | 1 | 1 |
| Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 1 | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 1 | 1 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | — | — | 1 | 1 |
| Premature menopause | D008594 | — | E28.31 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Strontium ranelate |
| INN | — |
| Description | Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2] |
Identifiers
| PDB | — |
| CAS-ID | 135459-87-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707306 |
| ChEBI ID | — |
| PubChem CID | 6918182 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
205 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use